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ABSTRACT 
On the basis of the traditional knowledge of treating solid tumor using Cardiospermum halicacabum gained attention to carry out the present 
work. The preliminary screening for determination of cytotoxicity of successive extract of C halicacabum (hexane, chloroform, ethyl acetate and 
ethanol) was performed through brine shrimp lethality assay and yeast growth rate cytotoxicity assay. Among the extracts, chloroform extract 
of C halicacabum exhibited highest cytotoxicity which was further investigated for anti-proliferative and cytotoxicity property in A-549 lung 
cancer cell line. Correspondingly, dose dependent effects on reduction of cell proliferation with prominent morphological abnormalities of A-
549 cells were observed under treatment with chloroform extract. Hemocompatibility assessment of chloroform extract, by hemolysis assay, 
revealed its compatibility towards RBC which in turn may prevent heamolytic anemia (myelosuppression) the most adverse effects of cancer 
chemotherapy.  Phytoconstituents of chloroform extract responsible for the cytotoxicity, anti-proliferative and hemocompatibiltiy was assessed 
by several chromatographic methods such as TLC, Column chromatography and HPLC which revealed the presence of flavonoids in chloroform 
extract of C halicacabum. Apparently the isolated flavonoids, in consistence with chloroform extract, exhibited similar effect on inhibition of 
proliferation of tumor cell line A-549. Therefore it could be evidenced from the current study that the C halicacabum, with its predisposed 
flavonoids, possesses anti-cancer property with least adverse effect on heamolysis. However detailed investigation on regulation of tumor cell 
proliferation and hemocompatability is required to bring C halicacabum as a potential candidate for cancer therapy.     
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In recent years, the usage of herbal based medicines and 
health supplements has been increased tremendously. 
Evidences for alternative and herbal based therapy are 
increasing exponentially worldwide1. In the last few decades 
resurgence of interest on plant derived natural products 
which forms a source of several drugs is elevated. 
Prevalence of cancer is being increased globally. High failure 
rate in obtaining successful cancer drugs with least adverse 
effect make the case further worsen. Drugs of natural origin 
especially plant derivatives gain advantage and being 
approved with the increased success rate. Almost fifty 
percentage of the anti-cancer drug available are from natural 
origin and natural derivatives.  
Vinblastine and Vincristine both isolated from Catharanthus 
roseus2 for treatment of Hodgkins disease, lymphosarcoma, 
leukemia in children. Teniposide and Etoposide developed 
from the anti-neoplastic lignans podophyllotoxins, a 
constituent of Podophyllum species are being used to treat 
testicular cancer, small cell lung cancer and lymphomas. 
Paclitaxel, a diterpenoid constituent of several Taxus 
species3 is effective in the treatment of metastatic breast 
cancer, ovarian cancer and has potential uses in the 
treatment of lung cancer, malignant melanoma. Irenotecan 
(analogue of Quinoline alkaloid camptothecin) first isolated 
from the Camptotheca acuminate4 but now obtained mostly 
from the Indian Mappia foetida Miers4 is being used in Japan 
for lung, ovarian and cervical cancer treatment.  
The pursuit of “bioactivity-guided fractionation” for plant 
extracts, using in vitro cell-based cytotoxicity assays, has 
served as the mainstay of anticancer drug discovery study, 
and has produced considerably valuable compounds thus 
far. In this regard, the aerial parts of Cardiospermum 
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halicacabum a tropical climber growing wild in Indian 
subcontinent are used for the treatment of hardened tumors 
in the Ayurvedic medicines. Hence in this present study the 
anti cancer activity of the selected fractions of the aerial 
parts of Cardiospermum halicacabum was carried to prove 
the traditional medical claim.  
Various extracts of Cardiospermum halicacabum have been 
reported to possess anti-plasmodial, anti-bacterial, anti-
inflammatory, anti-oxidant, anti-hyperglycemic and 
nephroprotective properties. It is also used as one of the 
major ingredient in traditional herbal formulations and 
products. Several scientific evidences are available for 
medicinal property of C halicacabum on various diseases, 
however no evidences are available for its anti-cancer 
property. 
In the present study various extracts of Cardiospermum 
halicacabum prepared under maceration technique with 
solvents of increasing polarity (hexane, chloroform, ethyl 
acetate, alcohol), were screened for its cytotoxic activity 
using brine shrimp lethality assay and yeast growth rate 
cytotoxicity assay. The efficacy of selected extract and its 
active fraction on inhibition of tumor cell was evaluated in 
lung cancer cell line (A-549 cells) followed by safety 
assessment by human RBCs-hemolytic assay. 
2. MATERIALS AND METHODS 
2.1. Collection of Specimen 
The plant specimens for the proposed study were collected 
from Sri Ramachandra University Campus. Care was taken to 
select healthy plants for the study. The Authentication of the 
plant specimen was carried out using standard methods5. It 
was authenticated by Prof. P. Jayaraman Director, Plant 
Anatomy Research    Centre, Tambaram, Chennai. 
2.2.  Preparation of Extracts 
The aerial parts of Cardiospermum halicacabum was washed 
with water, cut into small pieces, shade dried and powdered 
coarsely. The powdered aerial parts  of  Cardiospermum 
halicacabum (2 kg) were extracted exhaustively using 
different solvents with increasing polarity: 
Hexane>Chloroform>Ethyl acetate>Alcohol in an aspirator 
bottle at room temperature for 72 hours followed by 48 and 
24 hours. The filtrates were collected and distilled over 
boiling water bath under reduced pressure.  
2.3. Brine Shrimp Lethality Assay 
The brine shrimp lethality assay, proposed by Michael et al., 
6, is a useful tool for preliminary assessment of toxicity7. The 
procedure of the brine shrimp lethality assay is as follows. 
Brine shrimp (cysts) tin can stored at 4oc was brought to 
room temperature the previous day before use. 100mg of 
cysts were weighed, soaked in distilled water for half an 
hour and was transferred into a separating funnel containing 
sea water of pH 8.2 and the specific gravity 1.03, prepared 
from 33.33g of red sea rock salt dissolved in one liter of 
autoclaved distilled water. Aeration was provided through 
an aerator (motor). Illumination was provided through a 
100 watt bulb. After 12hr, cysts were hatched and the active 
nauplii were collected and used for the assay. 
Ten nauplii were taken vial containing 4 ml of brine (salt) 
solution and 1ml of each 6 different concentrations of test 
extracts. The standard was added to 4ml of brine solution 
and maintained at room temperature for 48 hr under light 
and surviving larvae were counted. The live ones and the 
dead ones were differentiated by their relative motilities, the 
one with low or no movements were counted as dead and 
those of normal movement were considered alive. 
Experiments were conducted along with control and 
different concentrations of the test substance in a set of 
three tubes per dose. The LC50 values were obtained by a 
plot of percentage of dead shrimp nauplii against the 
concentrations of the extracts.  
2.4. Hemolytic Assay 
The hemolytic assay of the active components was 
performed using the standard method. The hemolytic 
activity of extracts was determined using erythrocytes 
isolated from human red blood cells. Blood (4ml) collected 
from healthy individual was centrifuged at 450g for 
10minutes and washed with phosphate buffered saline (X3) 
of pH-7.4 followed by treatment with different 
concentrations of test samples (50 µg, 100 µg, 150 µg, 200 
µg). Final volume 50 µl of various concentrations of test 
samples with 40 µl PBS/ 90 µl of water (positive control) / 
90 µl of normal saline (negative control) were incubate with 
10 µl of  RBC suspension for 1hr at 37oC and centrifuged at 
200g for 5 minutes. The absorbency was measured in an UV 
spectrometer at 545nm wavelength. The percentage 
hemolysis was calculated using the below mentioned 
equation.  
                                       OD (test) – OD (negative)    × 100 
Percentage hemolysis = 
                                                        OD (positive) – OD (negative) 
2.4. Yeast Growth Rate Cytotoxicity Assay 
Yeast was reactivated in YEPD medium (Yeast Extract 
Peptone Dextrose) by a pure-culture (lyophilizated) and 
maintained in a molasses medium supplemented with 
KH2PO4 (8.36 mM), (NH4)2SO4 (5 mM), urea (38.75 mM), 
MgSO4.H2O (3.57 mM), ZnSO4.7H2O (0.10 mM), MnSO4.H2O 
(0.12 mM) and linolenic acid (0.11 mM). Cells from the late-
exponential growth phase were harvested by centrifugation 
at 800 gravity for 20 minutes and resuspended in double 
distilled water at a final concentration of 1g per 100 ml.  
Fermentation was carried out with 250 ml of YED sterilized 
(yeast extract 1% and dextrose 2%) medium in 500 ml 
Erlenmeyer flasks sealed with aluminum foil. Media was 
transferred into various boiling tubes with or without 50µM 
of cadmium concentration/ different concentrations (50 µg, 
100 µg, 300 µg, 500 µg) extracts with 1mL of final volume. 
All the tubes were inoculated with 1 mL of 1% yeast 
suspension and incubated in orbital shaker (70 RPM) at 30°C 
for 6 hours. Trypan blue staining was performed with 500 µl 
of cell suspension from each tubes at various time intervals 
(0, 60, 120, 180, 270 and 330 minutes) during fermentation. 
2.5. High Performance Thin Layer Chromatography 
(HPTLC) 
The fingerprinting of chloroform, extract of C halicacabum 
has been done using a 1010cm preactivated HPTLC silica 
gel 60F 254 plate. The chloroform extracts of C halicacabum 
have been prepared at a concentration of 1mg/ml in ethyl 
acetate and were spotted using CAMAG Linomat 5 
applicator. The method was optimized using solvent ratio 
and developed in a twin trough chamber, 20 10 cm at 250c. 
The plates were dried by hair dryer. The developed plates 
were scanned using CAMAG TLC scanner 3 and photo-
documented using CAMAG REPROSTAR 3.  
2.6. High Performance Liquid Chromatography (HPLC) 
Alcohol, water and hydrochloric acid at ratio of 50:20:8 and 
methanol, water and phosphoric acid at ratio of 100:100:1 
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was used as extraction solvent and mobile phase 
respectively.  
Standard and test solution of 20 µl was separately injected 
into the chromatography. Chromatogram was recorded and 
the areas for the major peaks were measured. The 
percentage of each flavonoid in the sample was calculated 
and expressed as flavones glycosides. 
                         2 F1m12.514p 
Percentage content    = 
                                                          F2m2 
2.7. Column Chromatography of Chloroform Extract of 
C. halicacabum 
The C. halicacabum chloroform extract 10gm was applied to 
a silica gel column (60 – 120 mesh) packed in hexane and 
eluted with solvents of varying polarity of hexane, hexane: 
chloroform, chloroform, chloroform: ethyl acetate, ethyl 
acetate, ethyl acetate: methanol and then methanol. Similar 
fractions were pooled based on TLC profiles. Fractions 
eluted with ethyl acetate: methanol (50:50) yielded crystals 
after concentration. It was soluble in methanol, ethyl acetate, 
and chloroform and insoluble in ether and hexane. It gave a 
pink color with concentrated hydrochloric acid and 
magnesium ribbon indicating it as a flavanoid. TLC of the 
fraction in BAW (4:1:5) gave a neat single streak of 0.77Rf 
.Since the isolated fraction showed a band instead of a spot it 
was suspected to be a mixture of flavanoids and hence the 
fraction was subjected for λmax determination. 
Three prominent peaks were obtained at 254nm, 268nm 
and 366nm respectively which were similar to that of the 
Luteolin. Theoretically it is given that Luteolin have peaks at 
255nm, 268nm and 350nm respectively (Harborne – 
Phytochemical Methods). The percentage content of 
flavanoids, expressed as flavones glycosides, was calculated 
using the below equation 
                                               2 F1m12.514p 
Percentage Content=    
                                                    F2m2 
2.8.  Microscopic Observation of A-549 Cell 
Morphology 
The morphological changes in the A-549 cells after 
treatment with Cardiospermum halicacabum crude extract 
and flavonoid fraction were observed under 10X 
magnification in inverted light microscope (Nikon). 
2.9. Anti-Proliferative Activity on Lung Cancer Cell Line 
The A-549 cells were procured from National Centre for Cell 
Science (NCCS), Pune, India. Cells were seeded in 96 well 
plates at a concentration of 5×104 cells per plate and 
incubated for a period of 24 hrs at 37oC in 5% CO2 regulated 
incubator. The cell were serum starved for 1 hr and treated 
with different concentrations of chloroform extract of 
Cardiospermum halicacabum isolated fraction in the range of 
7.5µg, 15 µg, 30 µg, 60 µg, 120 µg respectively for 24 hours. 
After incubation treatment medium was replaced with 200µl 
of DMEM containing 0.5 mg/ml of MTT and cells were 
allowed for 4 hours at 370c in 5% CO2. The MTT containing 
medium was removed and the formazan crystals formed in 
the cells were dissolved in 200µl of DMSO. Plate was left on a 
shaker for 5 minutes and read at 570nm in multiwell-plate-
reader. 
3. RESULTS AND DISCUSSION 
The brine shrimp lethality assay was performed to assess 
the cytotoxicity and anti-tumor properties of C. halicacabum. 
Figure 1 represents degree of lethality of brine shrimp in 
proportionate to the concentration of the respective C. 
halicacabum extracts. Determination of LC50 value revealed 
that the chloroform extract of C halicacabum exhibited 
prominent activity with LC50 value of 27.5 µg/ml, whereas 
hexane, ethanol and ethylacetate extract showed LC50 value 
of 92.1 µg/ml, 183.2 µg/ml and 915.2 µg/ml respectively. 
The significance of lethality of C. halicacabum extract on 
brine shrimp indicated the presence of cytotoxic 
components, which may probably possess anti-cancer 
activity. The above statement was supported by the 
cytotoxicity excreted by naturally derived potent anti-cancer 
drug curcumin (LC50 8.9 µg/ml), which was used as a 
positive control in the experiment. 
 
 
Figure 1: Brine Shrimp Lethality Assay. * p value < 0.05 compared with other extract of C halicacabum. 
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Further, the cytotoxicity of C. halicacabum extract was 
investigated in yeast system, Saccharomyces cerevisiae with 
cadmium as a positive control. Cadmium is an environmental 
toxicant, however its’ complexes with supramolecules or 
other metals regulates proliferation and metastasis of 
several in vitro tumor cell lines and suppresses tumor 
growth in mouse xenograft models8-10. Yeast growth rate 
cytotoxicity assay represents lethality and decreased 
viability of S. cerevisiae mediated by cadmium or chloroform 
extract of C. halicacabum. Chloroform extract of C. 
halicacabum, as in close with cadmium, exhibited dose and 
time depended reduction in viability of S. cerevisiae under 
50, 100, 300 or 500 µg/ml treatment concentrations for 1, 2, 
3, or 4 hr. 
The above mentioned preliminary cytotoxic evaluation of C. 
halicacabum extracts by brine shrimp lethality and yeast 
growth rate cytotoxicity assays represented the chloroform 
extracts to be effective among the other extracts (ethanol, 
hexane and ethyl acetate). The observation and significance 
of brine shrimp lethality and yeast growth rate cytotoxicity 
assays in screening anti-cancer drug was supported by the 
corresponding positive controls, curcumin and cadmium, 
which are established anti-cancer candidates.  
The cytotoxic effect of chloroform extract of C. halicacabum, 
in concert with anti-cancer property, was validated in lung 
cancer cell line (A549 cells) though morphological analysis 
and MTT assay. Dose dependent morphological changes 
were observed under the treatment of 20, 50 and 100 µg/ml 
of chloroform extract. Morphological abnormalities mediated 
by chloroform extract were observed as more number of 
round cells with misshapen and shrunken cell membrane.  
Correspondingly, proliferation of lung cancer line was also 
negatively affected by C. halicacabum chloroform extract 
with the increased rate of cell growth inhibition in dose 
dependent manner. Percentage of growth inhibition, 
calculated from MTT assay, indicated 16.3 to 63.0% reduced 
cell proliferation under the treatment concentration ranging 
from 7.5 to 120 µg/ml. 
According to national cancer institute, anemia is one of the 
most common side effects experienced by almost many 
cancer patients undergoing chemotherapy (NIH-National 
Cancer Institute (https://www.cancer.gov/about-
cancer/treatment/side-effects). It is necessary for any new 
anti cancer drug to possess lesser side effect. Therefore it 
was interested to assess the side effects of C. halicacabum 
chloroform extract especially on its’ haemocompatible 
property. Because myelosuppression, a progressive 
hemolytic anemia (hemolysis of RBC), is the most common 
complication manifested in cancer patients undergoing 
chemotherapy11, 12. Even mild to moderate anemia associated 
with therapeutic interventions immensely affect the 
functionality and quality of life in cancer patients. Hence it 
was astounding to find the haemocompatible property of 
chloroform extract of C. halicacabum. As represented in the 
figure 2, chloroform extract of C. halicacabum did not exhibit 
notable hemolytic property even in the range of 50 to 200 
µg/ml treatment concentrations. Thus, crude extract of C. 
halicacabum showed no hemolytic activity against human 
red blood cells which could be an added property for any 
anti-cancer drug candidate.  
 
 
Figure 2: Hemolytic Assay: * p value < 0.05 compared with negative control. 
 
Phytochemical analyses were carried out to examine the 
chemical constituents of chloroform extract of C 
halicacabum using several chromatographic techniques. 
HPLC analysis revealed that the chloroform extract of C. 
halicacabum contains 13 compounds of which apigenin 
(4.12 mg), luteolin (0.871 mg) and chryseriol  (0.112 mg) 
were estimated as 4.12 mg, 0.871 mg and 0.112 mg in 1g of 
chloroform extract.  The flavonoid rich fraction of 
chloroform extract subjected to column chromatography for 
isolation of the favonoids.  
The isolated fraction was then validated by its anti-
proliferative property on A549 lung cancer cell line. 
However the isolated flavanoids exhibited lower anti-
proliferative activity on A-549 lung cancer cell line when 
compared with the crude chloroform extract (Figure 4), 
which shows the influence of other non-flavanoids along 
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with flavanoids such as luteolin and apigenin.  Luteolin and 
apigenin are potential anti-cancer agents13,14 which possess 
hemocompatabile property of attenuating oxidative stress in 
erythrocytes14,15. Thus the current study provided the 
evidence for the presence of luteolin and apigenin along with 
non-flavonoids in chloroform extract of C. halicacabum 
which may be responsible for anti-cancer and 
haemoprotective activity of C. halicacabum.  
 
 
Figure 3: Yeast Growth Rate Cytotoxicity Assay: * p value < 0.05 compared with control. 
 




The current study revisited the anti-cancer property of C 
halicacabum which was used traditionally for cancer 
therapy. Though detailed investigation is required to 
elucidate the exact mode of action of C halicacabum, as a 
preliminary observation, the results of the present study 
suggested that the chloroform extract of C halicacabum 
possessed cytotoxicity property on lung cancer cell line A549 
due to the presence of non-flavonoids comppunds other than 
apigenin, luteolin and chryseriol. Further it can also be 
speculated from the results that the chloroform extract of C 
halicacabum may also be haemoprotective which is a 
substantial property for any anti-cancer drug to be 
considered for cancer chemotherapy.   
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